Gerrit Reepmeyer – författare

This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures.

Dieses Buch untersucht und beleuchtet die wichtigsten Herausforderungen, denen sich die pharmazeutische Industrie in einem zunehmend wettbewerbsorientierten Umfeld mit inflationären F&E-Investitionen und verschärftem Kostendruck stellen muss. Die Autoren stellen drei Quellen der pharmazeutischen Innovation vor: neue Managementmethoden in der Arzneimittelentwicklung, neue Technologien als Voraussetzung für Spitzenforschung und -entwicklung und neue Formen der Zusammenarbeit und Internationalisierung, wie z. B. Open Innovation in den frühen Phasen der Forschung und Entwicklung. Neue Modelle und Methoden werden anhand von Fallbeispielen aus Europa, den USA und Asien illustriert. Diese dritte, vollständig überarbeitete Auflage wurde erweitert, um die neuesten Entwicklungen im Bereich der offenen und kollaborativen Innovation, die größere strategische Bedeutung von Risikokapital und Investitionen in der Frühphase sowie die neue Palette an aufkommenden Technologien, die jetzt in der pharmazeutischen Innovation eingesetzt werden, zu berücksichtigen.

Dieses Buch untersucht und beleuchtet die wichtigsten Herausforderungen, denen sich die pharmazeutische Industrie in einem zunehmend wettbewerbsorientierten Umfeld mit inflationären F&E-Investitionen und verschärftem Kostendruck stellen muss. Die Autoren stellen drei Quellen der pharmazeutischen Innovation vor: neue Managementmethoden in der Arzneimittelentwicklung, neue Technologien als Voraussetzung für Spitzenforschung und -entwicklung und neue Formen der Zusammenarbeit und Internationalisierung, wie z. B. Open Innovation in den frühen Phasen der Forschung und Entwicklung. Neue Modelle und Methoden werden anhand von Fallbeispielen aus Europa, den USA und Asien illustriert. Diese dritte, vollständig überarbeitete Auflage wurde erweitert, um die neuesten Entwicklungen im Bereich der offenen und kollaborativen Innovation, die größere strategische Bedeutung von Risikokapital und Investitionen in der Frühphase sowie die neue Palette an aufkommenden Technologien, die jetzt in der pharmazeutischen Innovation eingesetzt werden, zu berücksichtigen.

This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures.

Pharmaceutical innovation is like gambling at roulette, only the stakes are higher. Considerably higher, since the most recent estimates put the costs of drug development at US$ 800 million to US$ 1 billion - per drug! This is equivalent to the price tag of the Empire State Building, when it was for sale a few years ago. In 2001, the major US and European pharmaceutical companies invested more than US$ 30 billion in R&D, at a higher R&D­ to-sales ratio than virtually any other industry, including chemicals, auto­ mobiles, electronics, aerospace, and computers. Delivering a blockbuster drug is the Holy Grail for any pharmaceutical company. But in the last decade the rules of developing blockbusters seem to have changed. On the one hand, more sophisticated screening technolo­ gies, genetic engineering, and expanding networks with biotechnology companies increase the probability of commercial success. Critical success factors include the discovery phase and a stronger outside-in orientation in the early innovation phase. After the implosion of the high-tech stock mar­ ket, biotechnology and other technology-driven opportunities may have lost some of their attractiveness for big pharma: a pipeline of solid and predictable innovations seems to be the highest goal of most pharmaceuti­ cal companies again. On the other hand, despite significant investments in pipeline management and novel technologies, there is still no recipe for ensuring a blockbuster hit.

Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.

Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.

The productivity in pharmaceutical research and development faces intense pres­ sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared to around US$ 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re­ cord level of close to US$ 1 billion today. As a result, any failure of a new sub­ stance in the R&D process can lead to considerable losses, and the risks of introduc­ ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year.